186 related articles for article (PubMed ID: 20799878)
21. Dose-toxicity models in oncology.
Adamina M; Joerger M
Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
[TBL] [Abstract][Full Text] [Related]
22. Designing transformative clinical trials in the cancer genome era.
Sleijfer S; Bogaerts J; Siu LL
J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
[TBL] [Abstract][Full Text] [Related]
23. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
Saijo N
Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
[TBL] [Abstract][Full Text] [Related]
24. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
25. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
26. New targets and challenges in the molecular therapeutics of cancer.
Eastman A; Perez RP
Br J Clin Pharmacol; 2006 Jul; 62(1):5-14. PubMed ID: 16842374
[TBL] [Abstract][Full Text] [Related]
27. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
Takimoto CH
Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662
[No Abstract] [Full Text] [Related]
29. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
30. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
[TBL] [Abstract][Full Text] [Related]
31. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.
Seymour L
Curr Pharm Des; 2002; 8(25):2279-84. PubMed ID: 12369856
[TBL] [Abstract][Full Text] [Related]
32. [Front-line drug discovery system for cancer].
Mizukami T
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
[TBL] [Abstract][Full Text] [Related]
33. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
34. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents.
O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026
[TBL] [Abstract][Full Text] [Related]
35. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?
Sargent D
Oncologist; 2010; 15 Suppl 1():19-23. PubMed ID: 20237213
[TBL] [Abstract][Full Text] [Related]
36. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
37. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
38. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
[TBL] [Abstract][Full Text] [Related]
39. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
40. Targeted approaches to childhood cancer: progress in drug discovery and development.
Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]